DK0863917T3 - Målrettede cytotoksiske anthracyclin-analoger - Google Patents

Målrettede cytotoksiske anthracyclin-analoger

Info

Publication number
DK0863917T3
DK0863917T3 DK96938216T DK96938216T DK0863917T3 DK 0863917 T3 DK0863917 T3 DK 0863917T3 DK 96938216 T DK96938216 T DK 96938216T DK 96938216 T DK96938216 T DK 96938216T DK 0863917 T3 DK0863917 T3 DK 0863917T3
Authority
DK
Denmark
Prior art keywords
nitrogen
halo
carbon
och2
excess
Prior art date
Application number
DK96938216T
Other languages
English (en)
Inventor
V Tulane University Med Andrew
A Tulane University Med Attila
Tulane University Med Ren-Zhi
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24247176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0863917(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Tulane filed Critical Univ Tulane
Application granted granted Critical
Publication of DK0863917T3 publication Critical patent/DK0863917T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK96938216T 1995-11-27 1996-11-14 Målrettede cytotoksiske anthracyclin-analoger DK0863917T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/562,652 US5843903A (en) 1995-11-27 1995-11-27 Targeted cytotoxic anthracycline analogs
PCT/EP1996/005029 WO1997019954A1 (en) 1995-11-27 1996-11-14 Targeted cytotoxic anthracycline analogs

Publications (1)

Publication Number Publication Date
DK0863917T3 true DK0863917T3 (da) 2004-01-19

Family

ID=24247176

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03010988T DK1384710T3 (da) 1995-11-27 1996-11-14 Syntese af heterocykliske forbindelser indeholdende fem- eller seks-leddede ringe
DK96938216T DK0863917T3 (da) 1995-11-27 1996-11-14 Målrettede cytotoksiske anthracyclin-analoger

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK03010988T DK1384710T3 (da) 1995-11-27 1996-11-14 Syntese af heterocykliske forbindelser indeholdende fem- eller seks-leddede ringe

Country Status (27)

Country Link
US (2) US5843903A (da)
EP (2) EP1384710B1 (da)
JP (2) JP3987575B2 (da)
KR (2) KR100445754B1 (da)
CN (2) CN1137136C (da)
AT (2) ATE401305T1 (da)
AU (1) AU709539B2 (da)
BR (1) BR9611647B1 (da)
CA (2) CA2471775C (da)
CZ (1) CZ297297B6 (da)
DE (2) DE69637604D1 (da)
DK (2) DK1384710T3 (da)
EA (1) EA001372B1 (da)
ES (2) ES2205067T3 (da)
HK (2) HK1017363A1 (da)
HU (1) HU229870B1 (da)
IL (3) IL134685A (da)
IS (2) IS2178B (da)
MX (1) MX9804119A (da)
NO (2) NO324035B1 (da)
NZ (1) NZ322054A (da)
PL (3) PL188786B1 (da)
PT (2) PT863917E (da)
SK (2) SK284392B6 (da)
UA (1) UA67722C2 (da)
WO (1) WO1997019954A1 (da)
ZA (1) ZA969709B (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576239B1 (en) 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
EP1135410B1 (en) 1998-11-13 2008-12-31 Cyclacel Limited Antennapedia homeodomain helix 3 derived translocation vectors
FR2786397B1 (fr) * 1998-11-30 2003-01-10 Synt Em Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc
FR2786398B1 (fr) * 1998-11-30 2002-12-27 Synt Em Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6528481B1 (en) 1999-02-16 2003-03-04 The Burnam Institute NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
US6380161B1 (en) 1999-06-21 2002-04-30 Inkine Pharmaceutical Company, Inc. Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions
AU1374601A (en) * 1999-11-12 2001-05-30 Angiotech International Ag Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
EP1452543A3 (en) * 2000-04-26 2005-08-03 BioSynthema, Inc RGD (ARG-GLY-ASP) coupled to (neuro)peptides
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
KR100420007B1 (ko) * 2001-04-25 2004-03-02 노영쇠 안트라사이클린 유도체 및 이를 포함하는 항암제
CA2461099A1 (en) * 2001-09-21 2003-04-10 The Administrators Of The Tulane Educational Fund Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
EP1531846A4 (en) * 2002-02-27 2006-04-19 Us Gov Health & Human Serv CONJUGATES OF LIGAND, LINK AND CYTOTOXIC AGENS, AND RELATED COMPOSITIONS AND USE PROCESSES
KR101003622B1 (ko) 2002-03-01 2010-12-24 더 어드미니스트레이터 오브 더 튜레인 에듀케이셔널 펀드 치료제 또는 세포독성제와 생물학적 활성 펩티드의컨쥬게이트
US7544767B2 (en) 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
AU2003235401B2 (en) * 2002-05-21 2008-09-25 Daiichi Sankyo Company, Limited Medicinal compositions containing ghrelin
ES2369640T3 (es) 2002-05-24 2011-12-02 Angiotech International Ag Composiciones y métodos para revestir implantes médicos.
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
MXPA05003183A (es) 2002-09-26 2005-06-08 Angiotech Int Ag Evolturas perivasculares.
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US20050043215A1 (en) 2003-02-19 2005-02-24 Tamara Minko Complex drug delivery composition and method for treating cancer
US8709998B2 (en) 2003-04-22 2014-04-29 Ipsen Pharma S.A.S. Peptide vectors
AU2007221964B2 (en) * 2003-04-22 2008-12-11 Ipsen Pharma S.A.S. Peptide vectors
US7097993B2 (en) 2003-06-25 2006-08-29 Wisconsin Alumni Research Foundation Method for identifying an agent that modulates type 1 phosphatidylinositol phosphate kinase isoform β661 activity
WO2005086951A2 (en) * 2004-03-10 2005-09-22 Threshold Pharmaceuticals, Inc. Hypoxia-activated anti-cancer agents
US20070060534A1 (en) * 2005-06-30 2007-03-15 Threshold Pharmaceuticals, Inc. Anthracycline analogs
JP5340155B2 (ja) * 2006-09-06 2013-11-13 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 細胞結合分子を有するジソラゾールのコンジュゲート及びそれらの誘導体、新規ジソラゾール誘導体、それらの製法ならびに使用
EP1900742A1 (en) 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
WO2008100591A2 (en) * 2007-02-14 2008-08-21 The General Hospital Corporation Modulation of nitric oxide signaling to normalize tumor vasculature
US8742076B2 (en) * 2008-02-01 2014-06-03 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
WO2009124468A1 (zh) * 2008-04-11 2009-10-15 天津和美生物技术有限公司 具有高活性的四环蒽醌类抗生素的衍生物及其制备和应用
MX2010011079A (es) * 2008-04-11 2012-06-01 Tianjin Hemay Bio Tech Co Ltd Derivados antibioticos de antraquinona tetraciclica con alta actividad, proceso para preparar los mismos y uso de estos.
CN102159248B (zh) * 2008-07-15 2013-09-11 健泰科生物技术公司 蒽环类衍生物缀合物、它们的制备方法以及它们作为抗肿瘤化合物的用途
CN102325545A (zh) 2009-02-20 2012-01-18 益普生制药股份有限公司 具有神经肽y受体结合化合物的细胞毒性缀合物
CN102050856B (zh) * 2009-11-03 2014-04-30 天津和美生物技术有限公司 具有高活性的表阿霉素的衍生物及其制备和应用
KR101897307B1 (ko) 2010-12-02 2018-09-10 네르비아노 메디칼 사이언시스 에스.알.엘. 모르폴리닐 안트라사이클린 유도체의 제조 방법
CN105198966B (zh) * 2014-06-26 2019-06-21 中国人民解放军军事医学科学院毒物药物研究所 GnRH类似物-细胞毒分子缀合物、其制备方法及用途
JP6602834B2 (ja) * 2014-06-30 2019-11-06 ターベダ セラピューティクス インコーポレイテッド 標的化コンジュゲートならびにその粒子及び製剤
EP3045540A1 (en) 2015-01-19 2016-07-20 Æterna Zentaris GmbH Enzymatic process for the regioselective manufacturing of N-Fmoc-doxorubicin-14-O-dicarboxylic acid mono esters
WO2017075495A1 (en) 2015-10-28 2017-05-04 Tarveda Therapeutics, Inc. Sstr-targeted conjugates and particles and formulations thereof
US10450340B2 (en) 2017-02-16 2019-10-22 Monopar Therapeutics Inc. 3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation
WO2021068051A1 (en) 2018-11-13 2021-04-15 Provincial Health Services Authority Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725350A (en) * 1972-04-26 1973-04-03 Commercial Soluents Corp Polymeric substances comprising the reaction product of melamine, aldehyde and oxazolidines
US4299822A (en) * 1980-06-09 1981-11-10 Sidney Farber Cancer Institute, Inc. N-Trifluoroacetyladriamycin-14-O-hemiglutarate and -hemiadipate and therapeutic compositions containing same
US4464529A (en) * 1982-07-20 1984-08-07 Sri International Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin
IL89220A (en) * 1988-02-11 1994-02-27 Bristol Myers Squibb Co Immunoconjugates of anthracycline, their production and pharmaceutical preparations containing them
US5217955A (en) * 1989-09-15 1993-06-08 Biomeasure, Inc. Treatment of cancer with peptide analog of bombesin, grp, litorin or neuromedin
US5304687A (en) * 1989-12-19 1994-04-19 Farmitalia Carlo Erba S.R.L. Morpholinyl derivatives of doxorubicin and process for their preparation
ATE143023T1 (de) * 1989-12-19 1996-10-15 Pharmacia Spa Chirale 1,5-diiodo-2-methoxy oder benzyloxy zwischenprodukte
EP0450461B1 (en) * 1990-04-06 1995-09-06 The Administrators of The Tulane Educational Fund LHRH Analogs
DE69110519T2 (de) * 1990-04-06 1995-11-30 Univ Tulane Somatostatinanaloge.
JP3169425B2 (ja) * 1992-03-27 2001-05-28 三共株式会社 アジドペンタンサイクリトール
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates

Also Published As

Publication number Publication date
SK62898A3 (en) 1999-06-11
CA2471775C (en) 2008-01-29
NO982252L (no) 1998-05-15
CA2471775A1 (en) 1997-06-05
EP1384710A1 (en) 2004-01-28
US6184374B1 (en) 2001-02-06
EA001372B1 (ru) 2001-02-26
AU709539B2 (en) 1999-09-02
JP2000502055A (ja) 2000-02-22
IL134685A (en) 2002-12-01
HUP9903771A3 (en) 2000-07-28
KR19990071672A (ko) 1999-09-27
PL191781B1 (pl) 2006-07-31
EA199800492A1 (ru) 1998-12-24
HUP9903771A2 (hu) 2000-02-28
DE69637604D1 (de) 2008-08-28
WO1997019954A1 (en) 1997-06-05
PT1384710E (pt) 2008-10-08
IS4734A (is) 1998-05-05
BR9611647B1 (pt) 2010-03-09
EP0863917A1 (en) 1998-09-16
EP1384710B1 (en) 2008-07-16
ES2310222T3 (es) 2009-01-01
SK284672B6 (sk) 2005-08-04
HK1052920B (zh) 2005-03-04
DK1384710T3 (da) 2008-11-17
JP3987575B2 (ja) 2007-10-10
IL119691A0 (en) 1997-02-18
ES2205067T3 (es) 2004-05-01
IL119691A (en) 2002-02-10
CN1202903A (zh) 1998-12-23
NZ322054A (en) 1999-04-29
UA67722C2 (en) 2004-07-15
PL188786B1 (pl) 2005-04-29
IL134685A0 (en) 2001-04-30
CZ135798A3 (cs) 1998-10-14
CZ297297B6 (cs) 2006-11-15
PL187230B1 (pl) 2004-06-30
AU7572296A (en) 1997-06-19
KR20040037176A (ko) 2004-05-04
CN1137136C (zh) 2004-02-04
NO20051111L (no) 2005-03-01
BR9611647A (pt) 1999-02-23
PT863917E (pt) 2004-02-27
DE69630233T2 (de) 2004-08-05
EP0863917B1 (en) 2003-10-01
US5843903A (en) 1998-12-01
JP4778405B2 (ja) 2011-09-21
IS2178B (is) 2006-12-15
CA2238574C (en) 2004-10-19
ATE251179T1 (de) 2003-10-15
CN1405127A (zh) 2003-03-26
JP2007045845A (ja) 2007-02-22
CN1166597C (zh) 2004-09-15
NO982252D0 (no) 1998-05-15
IS8567A (is) 2006-11-09
KR100467899B1 (ko) 2005-01-24
MX9804119A (es) 1998-09-30
ZA969709B (en) 1997-08-25
PL326865A1 (en) 1998-10-26
SK284392B6 (sk) 2005-03-04
IS2634B (is) 2010-06-15
HU229870B1 (en) 2014-10-28
NO324035B1 (no) 2007-07-30
HK1017363A1 (en) 1999-11-19
DE69630233D1 (de) 2003-11-06
HK1052920A1 (en) 2003-10-03
ATE401305T1 (de) 2008-08-15
KR100445754B1 (ko) 2004-12-08
CA2238574A1 (en) 1997-06-05

Similar Documents

Publication Publication Date Title
DK0863917T3 (da) Målrettede cytotoksiske anthracyclin-analoger
SE9301911D0 (sv) New peptide derivatives
BR9813835A (pt) Composto, composição farmacêutica e método de tratamento ou prevenção de uma desordem tromboembólica
BR9917080A (pt) Composto, composição farmacêutica, uso do composto e método de tratamento ou prevenção de uma disfunção tromboembólica
NZ302072A (en) 1,3-diamino propyl stereomeric derivatives and organic acid and inorganic salts of their amine intermediates in the preparation of retroviral protease inhibitors
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
MX9606494A (es) Compuestos organicos.
DK0941975T3 (da) Injiceringscement indeholdende korrosionshæmmere
MX9303587A (es) Producto para el cuidado de lentes de contacto, para lentes de contacto duros o blandos.
TW333533B (en) Novel indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase
FI970452A (fi) Leukotrieenin biosynteesin estäminen ureajohdannaisten avulla
AR015458A1 (es) Compuestos de tetrahidrofurano, y composicion farmaceutica que lo contiene.
TH13531EX (th) สารต่อต้านเชื้อราชนิดไซคลิค เพพไทด์ และกรรมวิธีเตรียมสารเหล่านั้น
EP1210948A4 (en) DRUGS FOR NERVOUS DISEASES
HUP9902556A2 (hu) Szinergetikus herbicid készítmény és eljárás annak alkalmazására
YU58300A (sh) Postupak za dobijanje 3-aminoalkohola
ATE221897T1 (de) Inhibitoren der blutplättchen-aggregation, die c- terminale aminosäurereste mit aminergen seitenketten enthalten